Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s

Theodoros Kelesidis, Carlee Moser, James H. Stein, Todd T Brown, Thuy Tien T Tran, Heather J. Ribaudo, Michael P. Dube, Otto O. Yang, Judith S. Currier, Grace A. McComsey

Research output: Contribution to journalArticle

Abstract

It is unclear whether differential roles of CD4<>+< versus CD8+ T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4<>+< T-cell senescence (ie, the percentage of CD28?CD57+ cells among CD4<>+< T cells ) and CD4<>+</CD8+ T-cell exhaustion (ie, the percentage of PD-1+ cells among CD4<>+</CD8+ T cells) decreased after ART. There were no changes inmarkers of CD8+ T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4<>+< and CD8+ T cells may have differential roles in HIV pathogenesis.

Original languageEnglish (US)
Pages (from-to)748-752
Number of pages5
JournalJournal of Infectious Diseases
Volume214
Issue number5
DOIs
StatePublished - Sep 1 2016

Keywords

  • Antiretroviral therapy
  • Biomarkers
  • Human immunodeficiency virus
  • Immune activation
  • Inflammation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s'. Together they form a unique fingerprint.

  • Cite this

    Kelesidis, T., Moser, C., Stein, J. H., Brown, T. T., Tran, T. T. T., Ribaudo, H. J., Dube, M. P., Yang, O. O., Currier, J. S., & McComsey, G. A. (2016). Changes in markers of t-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: Actg 5260s. Journal of Infectious Diseases, 214(5), 748-752. https://doi.org/10.1093/infdis/jiw253